Amicus Therapeutics (NASDAQ:FOLD) Given New $21.00 Price Target at Cantor Fitzgerald

Amicus Therapeutics (NASDAQ:FOLD) had its target price boosted by Cantor Fitzgerald from $20.00 to $21.00 in a report released on Thursday morning,Benzinga reports. Cantor Fitzgerald currently has an overweight rating on the biopharmaceutical company’s stock.

Several other research firms also recently weighed in on FOLD. Bank of America boosted their price target on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research note on Thursday, October 17th. JPMorgan Chase & Co. lowered their price target on shares of Amicus Therapeutics from $17.00 to $16.00 and set an “overweight” rating for the company in a research note on Friday, August 16th. StockNews.com downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, October 31st. Morgan Stanley lowered their price target on shares of Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating for the company in a research note on Friday, October 11th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a research note on Thursday. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $17.50.

Amicus Therapeutics Price Performance

Shares of Amicus Therapeutics stock traded up $0.01 on Thursday, hitting $10.99. 2,096,772 shares of the company traded hands, compared to its average volume of 2,730,403. The firm’s 50-day simple moving average is $11.14 and its 200 day simple moving average is $10.61. The company has a current ratio of 2.75, a quick ratio of 2.26 and a debt-to-equity ratio of 2.93. The company has a market cap of $3.26 billion, a P/E ratio of -32.32 and a beta of 0.68. Amicus Therapeutics has a 12-month low of $9.02 and a 12-month high of $14.57.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, meeting the consensus estimate of ($0.05). The firm had revenue of $126.67 million for the quarter, compared to analysts’ expectations of $121.21 million. Amicus Therapeutics had a negative net margin of 26.23% and a negative return on equity of 41.47%. The business’s quarterly revenue was up 34.0% on a year-over-year basis. During the same quarter last year, the company posted ($0.15) EPS. Analysts expect that Amicus Therapeutics will post -0.06 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Bradley L. Campbell sold 7,500 shares of the business’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $10.60, for a total transaction of $79,500.00. Following the transaction, the chief executive officer now owns 886,654 shares in the company, valued at $9,398,532.40. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CEO Bradley L. Campbell sold 7,500 shares of the business’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $10.60, for a total transaction of $79,500.00. Following the transaction, the chief executive officer now owns 886,654 shares in the company, valued at $9,398,532.40. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Bradley L. Campbell sold 7,901 shares of the business’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $12.50, for a total transaction of $98,762.50. Following the transaction, the chief executive officer now owns 886,654 shares in the company, valued at $11,083,175. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 30,401 shares of company stock valued at $352,038. Insiders own 2.20% of the company’s stock.

Institutional Investors Weigh In On Amicus Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Xponance Inc. grew its holdings in Amicus Therapeutics by 5.3% in the second quarter. Xponance Inc. now owns 18,555 shares of the biopharmaceutical company’s stock worth $184,000 after purchasing an additional 936 shares during the period. Hazlett Burt & Watson Inc. grew its holdings in shares of Amicus Therapeutics by 156.9% during the third quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 1,569 shares during the last quarter. Arizona State Retirement System grew its holdings in shares of Amicus Therapeutics by 2.6% during the second quarter. Arizona State Retirement System now owns 62,020 shares of the biopharmaceutical company’s stock valued at $615,000 after buying an additional 1,577 shares during the last quarter. American International Group Inc. grew its holdings in shares of Amicus Therapeutics by 1.3% during the first quarter. American International Group Inc. now owns 143,034 shares of the biopharmaceutical company’s stock valued at $1,685,000 after buying an additional 1,785 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Amicus Therapeutics by 21.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,727 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 1,884 shares during the last quarter.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.